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INTRODUCTION: Williams-Beuren syndrome (WBS; OMIM 194050) is caused by a hemizygous contiguous gene
microdeletion at 7q11.23. Supravalvular aortic stenosis, mental retardation, overfriendliness, and ocular and renal
abnormalities comprise typical symptoms in WBS. Although fluorescence in situ hybridization is widely used for
diagnostic confirmation, microsatellite DNA markers are considered highly informative and easily manageable.
OBJECTIVES: This study aimed to test the microsatellite markers for the diagnosis of Williams-Beuren syndrome, to
determine the size and parental origin of microdeletion, compare the clinical characteristics between patients with
different sizes of the deletion and parental origin.
METHODS: We studied 97 patients with clinical diagnosis of Williams-Beuren syndrome using five microsatellite
markers: D7S1870, D7S489, D7S613, D7S2476 and D7S489_A.
RESULTS AND DISCUSSION: Using five markers together, the result was informative in all patients. The most
informative marker was D7S1870 (78.4%), followed by D7S613 (75.3%), D7S489 (70.1%) and D7S2476 (62.9%). The
microdeletion was present in 84 (86.6%) patients and absent in 13 (13.4%) patients. Maternal deletions were found
in 52.4% of patients and paternal deletions in 47.6% of patients. The observed size of deletions was 1.55 Mb in 76/
84 patients (90.5%) and 1.84 Mb in 8/84 patients (9.5%). SVAS as well as ocular and urinary abnormalities were more
frequent in the patients with a deletion. There were no clinical differences in relation to either the size or parental
origin of the deletion.
CONCLUSION: Using these five selected microsatellite markers was informative in all patients, thus can be
considered an alternative method for molecular diagnosis in Williams-Beuren syndrome.
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INTRODUCTION
Williams-Beuren syndrome (WBS; OMIM 194050) is a
neurodevelopmental disorder described independently,1,2
as a syndrome involving facial appearance characteristics,
supravalvular aortic stenosis (SVAS) and mental retarda-
tion. In fact, WBS presents a wide collection of symptoms
affecting blood vessels, growth, intelligence, and behavior.
Children with this condition have distinctive ‘‘elfin’’ facial
features, a hoarse voice associated with growth, mental
retardation and an ‘‘engaging’’ personality;3,4 hyperacusis,
infantile hypercalcemia, prematurely wrinkled skin and
SVAS are also common symptoms.5-8
WBS is generally sporadic with an incidence of 1/13,700–
1/25,000 live births with no ethnic or sex preference,
although familial cases have been reported with apparent
autosomal dominant inheritance.9-11 Despite the consistency
of the overall clinical features, the broad spectrum of
anomalies and phenotypic variability frequently lead to a
significant difference in the number of patients diag-
nosed.12,13
The most common deletion, found in 90% to 95% of WBS
patients, spans a genomic region of ,1.55 Mb and is the
result of mispairing between the centromeric and medial
LCR blocks B (Bcen and Bmid).14-16 In 5% to 10% of cases,
the breakpoints are within the centromeric and medial LCR
blocks A (Acen and Amid), leading to an ,1.84 Mb
deletion.17,18 Atypical (,0.2 Mb to ,2.5 Mb) deletions may
be the leading cause of the substantial phenotypic varia-
bility among WBS patients.
Duplication of the WBS region occurs at half the
frequency of deletions with less distinctive and somehow
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opposite clinical features, such as deficits of social interac-
tion and an autistic-like phenotype.19-20 Autism was also
described in an atypically large deletion (2.4 Mb to 3.4 Mb)
telomeric to the WBS critical region.21 The presence of
inversions in WBS patients has also been reported.22,18
The origin of deletion occurs at the same frequency, and
there is no clear-cut clinical association between parental
imprinting and phenotype differences, except for hyperten-
sion and some aspects of growth, such as height, weight and
head circumference.17,13,23,24
Although fluorescence in situ hybridization (FISH) is
widely used and considered the gold standard for WBS
molecular diagnosis, the use of microsatellite DNA markers
has also been widely used and is considered highly
informative and easily manageable.15,17,25,26,27 Confirmation
of clinical suspicion is essential for clinical monitoring of the
patient and genetic counseling of the family.
In our previous study,28 we assessed the use of three
microsatellite markers (D7S1870, Hei and ELN 17/ exon 18)
in the confirmation of the diagnosis of 32 WBS patients.
They were informative in 78% of patients and uninformative
in 22%. The most informative marker was D7S1870. In the
present study, we maintained only the D7S1870 marker and
added four other microsatellite markers to determine the




A total of 97 patients with a clinical diagnosis of WBS (61
boys and 36 girls) were ascertained through clinical
evaluation by geneticists of the Unit of Clinical Genetics of
the Instituto da Crianc¸a, Hospital das Clı´nicas, Faculdade de
Medicina, Universidade (ICr-HC-FMUSP) de Sa˜o Paulo,
Brazil.
The clinical diagnosis was made between the ages of 1 and
16 years, with an average of 6 y 2 mo. The mean maternal and
paternal ages were 24 y 2 mo and 27 y, respectively.
Methods
The study was approved by the Institutional Review
Board, and written consent was obtained from all partici-
pants. The molecular study was performed in the
Laborato´rio de Investigac¸a˜o Me´dica do Instituto da
Crianc¸a (LIM-36).
Among the 97 patients, DNA from both parents was
obtained in 82 cases; in 13 cases, the molecular analysis was
performed only with maternal DNA and in two cases, only
with paternal DNA.
DNA was isolated from peripheral blood lymphocytes
using a salt precipitation technique29 and quantified in a
Nano Vue Plus spectrophotometer (GE, New Jersey, USA).
The five microsatellites markers used were D7S1870,
D7S489, D7S613 and D7S2476 inside the common 1.55-Mb
deletion; D7S489A was used to distinguish deletions of
1.84 Mb (Fig. 1).
Polymerase chain reaction. PCR reactions were carried
out in a total volume of 25 mL containing 50 ng of genomic
DNA, 0.2 mM of dNTP mix, 0.4 mM of the each
oligonucleotide, and 0.7 units of EasyTaq DNA Polymerase
(LGC, Sa˜o Paulo, Brazil). Samples were initially denatured
for 5 min at 94 C˚; followed by 35 cycles of 1 min at 94 C˚, 1 min
at the specific annealing temperature of each primer pair and
Figure 1 - Idiogram of chromosome 7 (7q11.23) illustrating the commonly deleted region and the relative localization of the tested
markers.29-32
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1 min at 72 C˚; and a final extension step of 15 min at 72 C˚.
Primer sequences and PCR conditions used in this study are
given in table 1. To check PCR amplification, 4 mL of the
reaction products were analyzed on 2% agarose gel stained
with ethidium bromide and visualized by UV exposure in an
AlphaImager HP (Alpha Innotech, Corp. San Leandro, CA).
Polyacrylamide gel. The PCR amplification product was
mixed in an equal volume of denaturing solution (99%
formamide, 0.01% bromophenol blue; 0.01% xylenecyanol
and 10 mM EDTA), denatured for 10 min at 95 C˚ and
separated by electrophoresis in a 7% denaturing
polyacrilamide gel with urea at a final concentration of
7.5 M. Electrophoresis was performed in a Mini-Proteans III
Cell apparatus (Bio-RadH). The electrophoresis conditions
were 105 V, 25 mA, and 2 W for two hours for the markers
D7S1870, D7S489, D7S613 and D7S2476 and 230 V, 60 mA,
and 5 W for four hours for marker D7S489A. The gels were
fixed in 10% ethanol, silver stained and stored in 10% acetic
acid until they could be photographed and interpreted.
The patient genotypes were compared with their parents.
Deletions were diagnosed as maternal when the proband
presented with gel-bands representing the allele marker
inherited only from the father. When, by chance, both
parents have the same alleles, the monoallelic inheritance of
the corresponding microsatellite marker by the proband
indicated an uninformative result.
We first used a two-step algorithm to identify the most
common 1.55-Mb deletion. We then tested the D7S489A
marker either to identify the larger 1.84-Mb deletion (in
those patients in which a deletion of at least one marker was
detected in the first step) or to confirm the lack of a deletion.
Statistical Analysis
Pairwise comparisons between clinical features of WBS
and the presence of deletion, clinical features and deletion
size and clinical features and parental origin of deletion
were tested for significance using two-tailed Fishers exact
test. A 2x2 contingency table was used to compare clinical
features. P analysis was performed in SPSS 13.0 software
and considered statistically significant when p # 0.05.
RESULTS
Using five markers (D7S1870, D7S489, D7S613, D7S2476
and D7S489A) were informative in all patients. The most
informative marker was D7S1870 (78.4%), followed by
D7S613 (75.3%), D7S489 (70.1%) and D7S2476 (62.9%)
(Table 2).
The microdeletion was present in 84/97 (86.6%) patients
and absent in 13 (13.4%) patients. A prototypic acrylamide
gel showing some of the results is shown in Figure 2.
All deletions were de novo, and none of the available
parents had any clinical manifestation of WBS. It was also
possible to determine the presence of a deletion for the 15
patients for whom DNA was available from only one of the
parents.
There was no difference in clinical features found in
patients with and without a deletion except SVAS as well as
ocular and urinary abnormalities, more frequent with
statistically significant association with a deletion. (Table 3)
Other cardiovascular diseases, such as pulmonary artery
stenosis, mitral valve prolapse and ventricular septum
defects, were similar between the two groups. Ocular
abnormalities observed were strabismus, stellate irides,
punctuate opacities in the lens, glaucoma and myopia.
Urinary abnormalities present included enuresis, diverticu-
losis, asymmetric kidneys, narrowing of the renal artery and
renal microlithiasis.
The observed size of deletions was 1.55 Mb in 76/84
patients (90.5%) and 1.84 Mb in 8/84 patients (9.5%). The
parental origin of deletion was maternal in 44/84 patients
(52.4%), and paternal deletions in 40/84 patients (47.6%).
There was no clinical difference in relation to either the size
of deletion or the parental origin of deletion.
Twenty-three patients were previously studied by FISH,
and 21 proved to have a deletion (FISH positive); whereas 2
Table 1 - Primers sequences, amplicon sizes and PCR conditions for the five microsatellites markers used.




D7S1870 F: TTCACTCAGGAAGTGGC 108 pb 2,0 mM Z51768 55˚C
R: TGGTGATGTGCTTTACTACG
D7S489 F: CTGTTGACTTTCCCACACTC 140-158 pb 1,5 mM Z16646 56˚C
R: GGCAACTCGAGACGTTAGTT
D7S613 F: CAGCCTGGGTAACAAAAGC 85 pb 1,4 mM L16300 55 /˚60˚C
R: CCTCCCTCCCTAATCCATG
D7S2476 F: GGGCAACATAGCACGATT 128-160 pb 2,0 mM Z53107 56˚C
R: CAGGAGTCAGTTAGATAAGGTCAC
D7S489_A F: GCACCTATGATCACAGCTTCTC 419 pb 2,0 mM BV097124 56˚C
R: ATGACATGAAGGTACTGGCCTT
*Accession number in the GeneBank; AT – anelling temperature; pb – pairs base.
Table 2 - Results of the analysis of microdeletions by microsatellite markers.
D7S1870 % D7S613 % D7S489 % D7S2476 %
Positive 65/97 67,1 66/97 68,1 58/97 59,8 56/97 57,7
Negative 11/97 11,3 7/97 7,2 10/97 10,3 5/97 5,2
Uninformative 21/97 21,6 24/97 24,7 29/97 29,9 36/97 37,1
Informative 76/97 78,4 73/97 75,3 68/97 70,1 61/97 62,9
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patients were FISH negative. Microsatellite marker analysis
of these cases revealed microdeletions in all patients,
including the two FISH negative patients.
DISCUSSION
The five microsatellite markers (D7S1870, D7S489,
D7S613, D7S2476, and D7S489A) used in our study were
informative in all patients.
The D7S1870 microsatellite marker showed the highest
power of detection, identifying 78.4% of the cases alone and
confirming the results found by previous studies.17,18,26,28,34-37
Another two markers (D7S613, D7S489) were also able to
diagnose over 70% of our patients, while the D7S2476
marker showed the poorest results (62.9%). These results
were similar to those found in the literature.17,25,26,37
The two best markers (D7S1870 and D7S613) in our study
were informative in 97.6% to the detect deletion when used
together. When the third marker, D7S489, was included
informative detection increased to almost 99%. To increase
the detection closer to 100%, additional useful markers will
need to be chosen.27,23,35-37
The microsatellite marker D7S489A was effective in the
analysis of the size of the deletion and in the confirmation of
the absence of fragments in the region critical for WBS. The
1.55-Mb deletion was found in 76/84 (90.5%) patients, and
the 1.84-Mb deletion found in 8/84 patients (9.5%); these
observed proportions are similar to those found in studies
in the literature.18,21
Clinical findings in our patients were similar in the groups
with a deletion and without a deletion, except for SVAS and
ocular and urinary abnormalities. There was also no relation-
ship between the size of the deletion and observed clinical
features. These results are similar to those found in litera-
ture,23,33 where the clinical features found in WBS patients
were very similar with both the 1.55-Mb and 1.84-Mb deletions.
In the 13 cases without a deletion, there is the possibility
of a deletion smaller than 1.0 Mb that is not detectable by
microsatellite markers; thus, this diagnostic should not be
ruled out.38,39
There was no significant difference between the frequen-
cies of maternal and paternal deletions (52.4% and 47.6%
respectively). The literature 18,23,28,36,37,40-42 is concordant
with our findings, except for one study,25 where the
maternal deletion was more frequent (77.8%) than the
paternal deletion (22.2%).
Despite the frequency of the paternal and maternal
deletions being very close, some authors have suggested a
slight tendency for deletion due to the effect of maternal
genomic imprinting, when all data are combined.25,36,42
The phenotypic aspects between the groups of the
patients with paternally (n = 44/84) and maternally derived
(n = 40/84) deletions were similar. Some reports in the
literature, however, suggest a parent-of-origin effect on
microcephaly and growth retardation in WBS.17,36
The FISH technique is currently considered the ‘‘gold
standard’’ for molecular diagnosis of WBS, but partial
microdeletions can lead to false negative results depending
on the sequence and composition of the probe used.25,30,38 In
the present study, the results obtained by FISH were
compared with microsatellite marker analysis. The results
were concordant, except for two negative FISH.
Other techniques in molecular biology are also being used
for the molecular diagnosis of WBS, such as quantitative real-
time PCR, multiplex ligation dependent probe amplification
(MLPA) and array comparative genomic hybridization
(aCGH), however, many other factors should be considered
in relation to the cost-benefit and practicality.43-45 In devel-
oped country, aCGH is currently the method of choice
for genome-wide screening for chromosome, but in the
developing country this technic is not in a disposal due to an
expensive cost.46,47
Figure 2 - Genotyping of the five microsatellites markers in WBS families. DNA fragments of those affected are always the first column
of each gel followed by DNA from the mother and the last column the DNA of the father. Black arrows indicate allelic loss.
Table 3 - Clinical fidings in patients with and without
deletion.
Clinical Findings With deletion
Without
deletion p
Frequency % Frequency %
Typical facies 100.0 100.0 –
Mental retardation 100.0 100.0 –
Friendly personality 92.5 91.7 –
Hyperacusis 81.9 58.3 0.120
Height (,5%) 51.2 23.1 0.059
Microcephaly 24.7 23.1 –
Cardiovascular disease 77.5 61.5 0.297
SVAS 58.1 12.5 0.022
Ocular abnormalities 65.2 20.0 0.012
Urinary abnormalities 48.1 16.7 0.041
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The diagnosis of WBS based on clinical assessments may be
difficult because of the great variability of its manifestations.
Laboratory tests to detect the microdeletion in 7q11.23 are
essential to confirm the clinical diagnosis for WBS. Although
fluorescence in situ hybridization (FISH) is widely used,
microsatellite DNA markers are considered highly informa-
tive and easily manageable for diagnostic confirmation.
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